Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: A single-center experience

Anti-Cancer Drugs

Volumn 20, Issue 2, 2009, Pages 105-108

  Mir, Olivier ^a,b   Alexandre, Jér̂ome ^a   Ropert, Stanislas ^a   Montheil, Vincent ^a   Martin, Idalie ^a   Durand, Jean Philippe ^a   Goldwasser, François ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Faculté de Médecine ^*  (France)

Author keywords

Chemotherapy; Elderly; Nonsmall cell lung cancer; Oxaliplatin; Vinorelbine

Indexed keywords

CISPLATIN; CORTICOSTEROID; NAVELBINE; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; COMORBIDITY; CONSTIPATION; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG FATALITY; DYSESTHESIA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTPATIENT CARE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 59449105557     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32831cdb51     Document Type: Article

References (26)

1. Loriot Y, Soria JC, Le Chevalier T. Expanding role of chemotherapy in lung cancer. Ann Oncol 2006; 17 (Suppl 10):×101-×107.
2. Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel, Ann Oncol 2004; 15:419-426.
3. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J Clin Oncol 2007; 25:1898-1907.
4. Gridelli C. Chemotherapy of non-small cell lung cancer in the elderly. Lung Cancer 2002; 38 (Suppl 3):S67-S70.
5. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer 2002; 38 (Suppl 2):S45-S50.
6. Von Hoff DD. Whither carboplatin?-A replacement for or an alternative to cisplatin? J Clin Oncol 1987; 5:169-171.
7. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003; 21:2664-2672.
8. Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004; 15:291-295.
9. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data metaanalysis. J Natl Cancer Inst 2007; 99:847-857.
10. Goldwasser F, Misset JL. Clinical use of oxaliplatin in solid tumors. Bull Cancer 2001; 88:S40-S44.
11. Raymond E, Chaney SG, Taamma A, Cvitkovic E, Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-1071.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
13. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rythmmodulated rate compared with constant rate. J Natl Cancer Inst 1990; 82:1046-1050.
14. Alexandre J, Gross-Goupil M, Nguyen M-L, Gornet J-M, Misset J-L, Goldwasser F. Evaluation of the nutritional and inflammatory status of cancer patients to assess the risk of severe hematologic toxicity of antineoplastic regimens. Ann Oncol 2003; 14:36-41.
15. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Institute's anticancer drug screen panel. Biochem Pharmacol 1996; 52:1855-1865.
16. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
17. Monnet I, Brienza S, Hugret F, Voisin S, Gastiaburu J, Saltiel JC, et al. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le traitement des tumeurs intra thoraciques. Eur J Cancer 1998; 34:1124-1127.
18. Cortinovis D, Bidoli P, Zilembo N, Fusi A, Bajetta E. Oxaliplatin doublets in non-small cell lung cancer: a literature review. Lung Cancer 2008; 60:325-331.
19. Franciosi V, Barbieri R, Aitini E, Vasini G, Cacciani GC, Capra R, et al. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 2003; 41:101-106.
20. Monnet I, Soulié P, de Cremoux H, Saltiel-Voisin S, Bekradda M, Saltiel JC, et al. Phase l/ll study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2001; 19:458-463.
21. Monnet I, de Cremoux H, Soulié P, Saltiel-Voisin S, Bekradda M, Saltiel JC, et al. Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol 2002; 13:103-107.
22. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16:2459-2465.
23. Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994; 5:37-42.
24. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad R Presant CA, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002; 94:291-297.
25. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non- small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218.
26. Le Chevalier T, Thezenas S, Breton J, Pujol J, Coudert B, Sun X, et al. J Clin Oncol 2006; 24 (Suppl 18). ASCO Annual Meeting Proceedings Part I: 7097 (abstract).